DeepMed Research

Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide

Not Applicable

Conditions: Diabetic Neuropathic Pain

Interventions: Drug: insulin
Drug: Liraglutide

First Posted Date: 2019-10-24

Last Posted Date: 2019-10-25

Lead Sponsor: Fudan University

Target Recruit Count: 60

Registration Number: NCT04137328

Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC

Phase 2

Conditions: NSCLC Stage IV

Interventions: Drug: Pemetrexed
Drug: Carboplatin
Drug: Anlotinib

First Posted Date: 2019-10-23

Last Posted Date: 2019-10-23

Lead Sponsor: Fudan University

Target Recruit Count: 105

Registration Number: NCT04136535

Locations: 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China

A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)

Phase 2

Conditions: Triple-Negative Breast Cancer

Interventions: Drug: camrelizumab in combination with nab-paclitaxel and famitinib

First Posted Date: 2019-10-17

Last Posted Date: 2022-01-11

Lead Sponsor: Fudan University

Target Recruit Count: 46

Registration Number: NCT04129996

Locations: 🇨🇳
Zhi-Ming Shao, Shanghai, China

Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)

Phase 3

Completed

Conditions: Primary Breast Cancer

Interventions: Drug: Docetaxel
Drug: Paclitaxel
Drug: Cyclophosphamide
Drug: Epirubicin
Drug: 5-fluorouracil

First Posted Date: 2019-10-15

Last Posted Date: 2020-02-26

Lead Sponsor: Fudan University

Target Recruit Count: 2079

Registration Number: NCT04127019

SIB in Upper Thoracic Esophageal Squamous Cell Carcinoma

Phase 2

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Radiation: Simultaneous integrated boost intensity-modulated chemoradiotherapy

First Posted Date: 2019-10-04

Last Posted Date: 2019-10-04

Lead Sponsor: Fudan University

Target Recruit Count: 65

Registration Number: NCT04115618

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC

Phase 2

Conditions: NSCLC Stage IV

Interventions: Drug: GM-CSF
Drug: Sintilimab
Radiation: SBRT

First Posted Date: 2019-09-26

Last Posted Date: 2019-09-26

Lead Sponsor: Fudan University

Target Recruit Count: 63

Registration Number: NCT04106180

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen

Phase 2

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: Apatinib
Drug: S-1 capsule
Drug: Irinotecan

First Posted Date: 2019-09-24

Last Posted Date: 2019-11-05

Lead Sponsor: Fudan University

Target Recruit Count: 126

Registration Number: NCT04101929

Locations: 🇨🇳
Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China

Sentinel Node Biopsy Vs Observation After Axillary PET

Not Applicable

Recruiting

Conditions: Breast Cancer

Interventions: Procedure: SLNB is spared

First Posted Date: 2019-08-28

Last Posted Date: 2020-07-13

Lead Sponsor: Fudan University

Target Recruit Count: 1528

Registration Number: NCT04072653

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment

Recruiting

Conditions: Metastases
Neuroendocrine Tumors
Surgery

Interventions: Other: system treatment
Procedure: system treatment and surgery

First Posted Date: 2019-08-26

Last Posted Date: 2019-09-24

Lead Sponsor: Fudan University

Target Recruit Count: 180

Registration Number: NCT04066322

Locations: 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China

FSRT in Breast Cancer Patients With Brain Metastases

Phase 2

Conditions: Breast Cancer
Brain Metastases

Interventions: Radiation: Fractionated stereotactic radiotherapy(FSRT)

First Posted Date: 2019-08-19

Last Posted Date: 2019-08-19

Lead Sponsor: Fudan University

Target Recruit Count: 170

Registration Number: NCT04061408

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy